Therapy with the nonpeptide endothelin receptor antagonist 97-139 in a murine model of congestive heart failure. Reduction of cardiac mass and myofiber hypertrophy

Abstract

Endothelin-1 (ET-1) is a potent vasoconstrictor. This peptide exerts numerous effects on the heart, including regulation of cardiomyocyte growth during hypertrophy. The effects of the structurally novel, nonpeptide, ET-1-selective, competitive antagonist (ETA) 97-139 were investigated in mice with congestive heart failure (CHF) and myocardial hypertrophy. Morphological and microscopical analyses were conducted on day 56 after viral inoculation following 28 day treatment with 99-139. Eight week-old DBA2 mice were intraperitoneally inoculated with encephalomyocarditis virus at a dose of 500 pfu/mouse. The 30 mice were divided into two groups-an ETA treated group and an untreated group. Heart weight (HW) in the infected group was significantly (p < 0.05) increased compared to that in the uninfected group. HW and the HW/body weight (BW) ratio were significantly (p < 0.05) reduced in the ETA treated group compared with the untreated group (HW; 127.7 ± 6.2 mg vs 144.3 ± 4.2 mg, HW/BW; 4.9 ± 0.9 x 10-3 vs 5.4 ± 0.5 x 10-3). Myofiber diameter in the ETA treated group was significantly reduced compared with the untreated group (12.1 ± 1.5 μm vs 14.3 ± 1.9 μm). These results suggest the ET-1 receptor antagonist 97-139 has an effect on the reduction of cardiac mass and myofiber hypertrophy, and that 97-139 may be a useful agent for CHF due to viral myocarditis.